Rare diseases and orphan drugs.
作者信息
Aronson J K
出版信息
Br J Clin Pharmacol. 2006 Mar;61(3):243-5. doi: 10.1111/j.1365-2125.2006.02617.x.
Abstract
摘要
相似文献
1
Rare diseases and orphan drugs.罕见病与孤儿药。
Br J Clin Pharmacol. 2006 Mar;61(3):243-5. doi: 10.1111/j.1365-2125.2006.02617.x.
2
[Orphan diseases].[罕见病]
Recenti Prog Med. 1993 Nov;84(11):786-93.
3
Drugs for rare diseases: mixed assessment in Europe.罕见病药物：欧洲的综合评估
Prescrire Int. 2007 Feb;16(87):36-42.
4
[Hope for patients with rare diseases--"orphan" drugs].[罕见病患者的希望——“孤儿”药]
Cas Lek Cesk. 2006;145(4):296-300.
5
[Orphan drugs. Drugs for treatment of rare diseases].[孤儿药。用于治疗罕见病的药物]
Med Monatsschr Pharm. 2004 Aug;27(8):256-9.
6
Assessing the economic challenges posed by orphan drugs.评估罕见病药物带来的经济挑战。
Int J Technol Assess Health Care. 2007 Winter;23(1):36-42. doi: 10.1017/S0266462307051550.
7
[Orphan drugs--medications for patients with rare diseases].[孤儿药——用于罕见病患者的药物]
Ugeskr Laeger. 2006 Jun 5;168(23):2236-8.
8
[Orphanet and the Dutch Steering Committee Orphan Drugs. A European and Dutch databank of information on rare diseases].[欧洲罕见病组织及荷兰孤儿药指导委员会。欧洲和荷兰罕见病信息数据库]
Ned Tijdschr Tandheelkd. 2008 Nov;115(11):621-3.
9
Rare diseases, orphan drugs, and orphaned patients.罕见病、孤儿药与被忽视的患者。
Mol Interv. 2006 Aug;6(4):186-91. doi: 10.1124/mi.6.4.2.
10
Orphan drug development across Europe: bottlenecks and opportunities.欧洲孤儿药的研发：瓶颈与机遇
Drug Discov Today. 2008 Aug;13(15-16):670-6. doi: 10.1016/j.drudis.2008.05.001. Epub 2008 Jun 24.
引用本文的文献
1
Personal Health Record Software for Neuroendocrine Tumors: Patient-Centered Design Approach.神经内分泌肿瘤的个人健康记录软件：以患者为中心的设计方法。
JMIR Hum Factors. 2025 Jun 3;12:e68788. doi: 10.2196/68788.
2
Therapeutic Application of mRNA for Genetic Diseases.信使核糖核酸在遗传性疾病中的治疗应用。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 May-Jun;17(3):e70019. doi: 10.1002/wnan.70019.
3
Integrating Machine Learning-Based Approaches into the Design of ASO Therapies.将基于机器学习的方法整合到反义寡核苷酸疗法的设计中。
Genes (Basel). 2025 Feb 2;16(2):185. doi: 10.3390/genes16020185.
4
Global insight into rare disease and orphan drug definitions: a systematic literature review.对罕见病和孤儿药定义的全球洞察：一项系统的文献综述。
BMJ Open. 2025 Jan 25;15(1):e086527. doi: 10.1136/bmjopen-2024-086527.
5
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.用于指导临床试验设计和监管决策的模型驱动药物发现与开发方法：中东和北非地区入门指南
Saudi Pharm J. 2024 Dec;32(12):102207. doi: 10.1016/j.jsps.2024.102207. Epub 2024 Nov 27.
6
The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative.血液学临床试验中整合多样性、公平性和包容性的路线图：美国血液学会倡议。
Blood Adv. 2025 Feb 25;9(4):687-695. doi: 10.1182/bloodadvances.2024013945.
7
Diet and Nutrients in Rare Neurological Disorders: Biological, Biochemical, and Pathophysiological Evidence.罕见神经疾病中的饮食与营养：生物学、生物化学和病理生理学证据。
Nutrients. 2024 Sep 15;16(18):3114. doi: 10.3390/nu16183114.
8
Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs.阿联酋罕见病药物多标准决策分析工具的开发。
Cureus. 2024 Feb 29;16(2):e55215. doi: 10.7759/cureus.55215. eCollection 2024 Feb.
9
Top Selling (2026) Small Molecule Orphan Drugs: A Journey into Their Chemistry.畅销（2026）小分子孤儿药：探寻其化学本质。
Int J Mol Sci. 2023 Jan 4;24(2):930. doi: 10.3390/ijms24020930.
10
Orphan rare diseases - The unified airways and its importance for the otorhinolaryngologist.罕见病——统一气道及其对耳鼻喉科医生的重要性。
Braz J Otorhinolaryngol. 2022 Nov-Dec;88 Suppl 5(Suppl 5):S1-S3. doi: 10.1016/j.bjorl.2022.12.003.
本文引用的文献
1
Orphan drug development is progressing too slowly.罕见病药物研发进展过于缓慢。
Br J Clin Pharmacol. 2006 Mar;61(3):355-60. doi: 10.1111/j.1365-2125.2006.02579.x.
2
75 years of opioid research: the exciting but vain quest for the Holy Grail.75年的阿片类药物研究：对圣杯的追寻令人兴奋却徒劳无功。
Br J Pharmacol. 2006 Jan;147 Suppl 1(Suppl 1):S153-62. doi: 10.1038/sj.bjp.0706435.
3
Orphan drugs and the NHS: should we value rarity?孤儿药与英国国家医疗服务体系：我们应该重视罕见病吗？
BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016.
4
An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity.对南非开普敦112例急性卟啉症发作的分析：急性间歇性卟啉症和杂合性卟啉症在易感性和严重程度上存在差异的证据。
Medicine (Baltimore). 2005 Jan;84(1):48-60. doi: 10.1097/01.md.0000152454.56435.f3.
5
Application of tissue culture methods to epidemiological studies of poliomyelitis.组织培养方法在脊髓灰质炎流行病学研究中的应用。
Am J Public Health Nations Health. 1954 May;44(5):571-80. doi: 10.2105/ajph.44.5.571.
6
Two decades of orphan product development.二十年的孤儿药产品研发。
Nat Rev Drug Discov. 2002 Oct;1(10):821-5. doi: 10.1038/nrd919.
7
Orphan drugs: legal aspects, current situation.孤儿药：法律层面、现状
Haemophilia. 2002 May;8(3):194-8. doi: 10.1046/j.1365-2516.2002.00643.x.
8
HGV: the identification, biology and prevalence of an orphan virus.
Liver. 1998 Jun;18(3):143-55. doi: 10.1111/j.1600-0676.1998.tb00142.x.
9
A review of alcohol clearance in humans.
Alcohol. 1998 Feb;15(2):147-60. doi: 10.1016/s0741-8329(97)00110-9.
10
Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.对孤啡肽/孤啡肽FQ受体（ORL1）具有高亲和力的肽的结合及体外活性
J Pharmacol Exp Ther. 1997 Nov;283(2):735-41.
Zotero 插件